CN Patent
CN1788001B — 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4-二(苯氨基)嘧啶
Assigned to Novartis AG · Expires 2010-09-22 · 16y expired
What this patent protects
本发明公开了式(I)的新嘧啶衍生物, 它们的制备方法、它们作为药物用于治疗赘生性疾病、炎性和免疫系统病症的用途和包含它们的药物组合物。
USPTO Abstract
本发明公开了式(I)的新嘧啶衍生物, 它们的制备方法、它们作为药物用于治疗赘生性疾病、炎性和免疫系统病症的用途和包含它们的药物组合物。
Drugs covered by this patent
- Zykadia (ceritinib) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.